Youth Mental Health Treatment Trials Still Leave Many Groups Behind, Review Finds

A major systematic review and meta-analysis published in Nature Mental Health has turned a critical lens on one of the most quietly persistent problems in youth mental health research: who actually gets studied when scientists test drugs and supplements for young people with psychiatric disorders. The review, which examined pharmacological and nutraceutical interventions in child and adolescent mental health, argues that the evidence base underpinning everyday clinical decisions may not represent the full diversity of the young populations those treatments are meant to serve. The finding lands at a moment when prescriptions for antidepressants, antipsychotics and stimulants in children and teenagers continue to rise across many countries, while families increasingly turn to over-the-counter nutritional supplements in the hope of gentler alternatives.

The central concern is representativeness. When a medication is tested in clinical trials, the participants enrolled in those trials define the boundaries of what medicine can confidently claim about the drug’s benefits and harms. If trial populations skew toward certain ages, sexes, ethnic backgrounds, income levels or geographic regions, then the resulting evidence inherits those blind spots. For young people, whose brains and bodies are still developing and who span an enormous developmental range from early childhood to late adolescence, the consequences of unrepresentative samples can be particularly consequential. A dose that is safe and effective for a sixteen-year-old may behave very differently in an eight-year-old, yet many trials lump broad age bands together or exclude younger children altogether.

The review also highlights inclusivity, a related but distinct concept. Representativeness asks whether trial participants mirror the real-world population of patients; inclusivity asks whether historically marginalized groups have been deliberately included at all. These include young people from racial and ethnic minority backgrounds, those from low- and middle-income countries, youth with intellectual disabilities or neurodevelopmental conditions, LGBTQ+ adolescents who carry elevated rates of depression and anxiety, and young people with multiple co-occurring diagnoses who are routinely excluded from trials by strict eligibility criteria. Each exclusion narrows the map of who the evidence actually describes, and each gap forces clinicians to extrapolate, sometimes with little justification, when treating patients who do not resemble the trial sample.

Methodologically, the study followed the established architecture of systematic review and meta-analysis. The researchers systematically searched the literature for randomized controlled trials of pharmacological treatments, such as antidepressants, antipsychotics, mood stabilizers and stimulants, and nutraceutical interventions, including omega-3 fatty acids, vitamins, minerals and other nutritional supplements, in youth mental health disorders. By pooling data across studies, a meta-analysis can deliver more precise estimates of treatment effects than any single trial, but that precision is only meaningful if the underlying trials are themselves representative. The review therefore evaluated not just whether treatments work, but who was included in the trials that generated the evidence, and how transparently those characteristics were reported.

One of the recurring frustrations the review identifies is incomplete reporting. Many trials fail to document the demographic composition of their samples in adequate detail, or report race, ethnicity and socioeconomic status inconsistently across studies and countries. Without standardized, granular reporting, it becomes nearly impossible to determine whether a treatment’s measured effect holds across subgroups, or whether adverse events fall disproportionately on some groups. This is not merely a bookkeeping problem. Regulatory decisions, clinical guidelines and prescribing habits all rest on published trial data, and gaps in that data propagate silently into everyday care. A clinician prescribing fluoxetine to an adolescent from a background never studied in the pivotal trials is, in effect, conducting an uncontrolled experiment.

The nutraceutical side of the analysis raises its own distinctive concerns. Nutritional supplements occupy a regulatory gray zone in many jurisdictions: they are widely available without prescription, heavily marketed to families, and often perceived as natural and therefore safe. Yet the trials testing omega-3 fatty acids, vitamin D, zinc and related compounds in youth depression, ADHD and anxiety tend to be smaller, more heterogeneous and less demographically documented than pharmaceutical trials. If supplement trials under-represent certain populations even more severely than drug trials, then the booming consumer market for youth supplements rests on an even thinner evidential foundation than the pharmaceutical one, a point with significant public health implications given how many families self-administer these products without medical supervision.

Geographic concentration compounds the problem. The majority of youth psychopharmacology trials are conducted in a small number of high-income countries, principally the United States, parts of Europe and Australia. Yet most of the world’s young people live elsewhere, with different genetic ancestries, diets, environmental exposures, healthcare access and cultural frameworks for understanding mental distress. Findings generated in Boston or London may not transfer cleanly to Lagos, Jakarta or rural Brazil. The review’s emphasis on this imbalance echoes a broader movement in global health research calling for decolonized evidence production, in which research agendas, funding and trial sites better reflect the populations that carry the greatest burden of disease.

Why do these gaps persist? The review situates the problem within the structural economics of clinical research. Trials are expensive, and sponsors recruit participants where recruitment is easiest and fastest, which typically means urban academic centers in wealthy countries serving patients who are insured, English-speaking, stable enough in their illness to meet protocol requirements, and reachable through existing healthcare networks. Strict exclusion criteria, designed to produce clean data by minimizing confounders, systematically screen out the very complexity that characterizes real-world patients: comorbidities, concomitant medications, unstable housing, intellectual disability. The result is a self-reinforcing loop in which evidence is generated on the most accessible patients and then applied, with growing unease, to everyone else.

The path forward, as the review frames it, involves concrete and measurable reforms. Trial registries and publications should mandate comprehensive demographic reporting using standardized categories. Funders and regulators can require diversity plans as a condition of approval, in the way that recent regulatory guidance in several countries has begun to demand. Researchers can design trials with broader eligibility criteria, adaptive designs that accommodate comorbidity, and recruitment strategies that reach community settings rather than relying solely on specialty clinics. Journals can refuse publication of trials that omit key demographic data. None of these steps is technically difficult; the obstacle has been inertia and the absence of systematic accountability, which this review begins to supply by quantifying the extent of the problem.

For clinicians and families, the immediate message is one of informed caution rather than alarm. The treatments studied in youth mental health, from SSRIs to omega-3 supplementation, have accumulated substantial evidence for certain populations and certain conditions, and no one should abandon effective care on the basis of representativeness concerns alone. But the review makes clear that the confidence clinicians can justifiably place in any given treatment is partly a function of who was studied, and that this confidence is currently unevenly distributed. Closing the gap between trial populations and real-world youth is not an abstract exercise in research ethics. It is a prerequisite for evidence-based mental health care that works, and is known to work, for every young person who walks through the clinic door.

Subject of Research: Representativeness and inclusivity of trial populations in pharmacological and nutraceutical interventions for youth mental health disorders

Article Title: Representativeness and inclusivity in pharmacological and nutraceutical interventions in youth mental health disorders: a systematic review and meta-analysis

Article References: Aymerich, C., Torres-Cortés, J., Melillo, A., Pedruzo, B., Catalan, A., Ibarretxe, O., Nosarti, C., Rubia, K., Arango, C., Shaw, P., Ani, C., Huang, H. C.-H., Dubicka, B., Kelleher, I., Fusar-Poli, P., Cortese, S., & Salazar de Pablo, G. (2026). Representativeness and inclusivity in pharmacological and nutraceutical interventions in youth mental health disorders: a systematic review and meta-analysis. Nature Mental Health. https://doi.org/10.1038/s44220-026-00722-5

Image Credits: AI Generated

DOI: 10.1038/s44220-026-00722-5

Keywords: youth mental health, systematic review, meta-analysis, pharmacological interventions, nutraceuticals, clinical trial diversity, adolescent psychiatry, health equity, representativeness, inclusivity, pediatric psychopharmacology, global health